StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

438 Study Matches

An Open-Label, Pilot Clinical Trial To Test The Efficacy Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection

We have determined that the microbes (bacteria) in the colon can play a role in causing and preventing complications of colon surgery. While the surgical bowel prep before surgery eliminates the harmful bacteria, it also eliminates the beneficial bacteria that aid wound healing. The purpose of this study is to determine if we can restore the presence of good bacteria (also known as ‘intestinal microbiota’) in the colon by transplanting them from a healthy donor.

Principal Investigator: Cyrus Jahansouz
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023336
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 75 years old
• having surgery for unresectable polyps, early-stage colon cancer (Stage 1 or 2) and don't expect to have chemotherapy or diverticulitis
• able to provide fecal samples
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• history of inflammatory bowel disease (Crohn's, Ulcerative Colitis)
• women who are pregnant or breastfeeding
• presence of ileostomy or colostomy
• history of solid organ or bone marrow transplant
• history of celiac disease
• receiving cancer chemotherapy, immunotherapy, or radiation
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Cancer, Digestive & Liver Health
Keywords: bowel resection, bowel surgery, Clinics and Surgery Center (CSC), colon cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

ConnectedNest: a digital platform connecting individuals with cancer to social care

Social determinants of health (SDoH) like housing instability, food insecurity, and financial burden, for example, can negatively affect people dealing with cancer. With new cancer treatments and higher costs for patients, people dealing with cancer may worry more about those issues. The goal of this study is to compare the ways people with cancer are connected to resources addressing specific needs and how those connections help their overall well-being. The research study will take about five months and participants will spend around one hour on research activities (each survey would take less than 15 minutes). The time you spend following up on helpful resources is completely up to participants.

Principal Investigator: Helen Parsons
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022167
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• undergoing active cancer therapy or in survivorship
• must be able to read and write in English
• seen in a participating Minnesota oncology clinic
Exclusion Criteria:

• children
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

HM2023-43: A phase 2 trial of tafasitamab in combination with lenalidomide+rituximab in treatment-naive follicular lymphoma and marginal zone lymphoma

This study is to see if patients who get tafasitamab in addition to the standard regimen of lenalidomide and rituximab when they are just starting treatment are more likely to stay in remission after treatment than those who do not. We expect that participants will be in this research study for approximately 3 years total. Patients will be on active treatment for approximately 1 year.

Principal Investigator: Sanjal Desai
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023899
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• confirmed marginal zone lymphoma
• have not received systemic therapy for lymphoma
• need treatment because of bulky disease, associated symptoms, or causing problems with vital organs (heart, spleen, lung)
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• active HIV, Hepatitis B, Hepatitis C
• prior history of lenalidomide use
• history of another cancer in the past 5 years
• women who are pregnant or breastfeeding
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), Follicular Lymphoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy

This study aims to quantify the rates of cervical cancer screening and endometrial sampling prior to gender-affirming hysterectomy, assess the need for these tests in TGD individuals, and explore patient-centered options for these tests.

Principal Investigator: Meredith Wise
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023022
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• able to understand, speak, read, and write in English
• have undergone hysterectomy, or plan to have a hysterectomy
• people who are transgender and gender diverse
Exclusion Criteria:

• on the study’s community advisory board
Conditions: Cancer, Community Health
Keywords: Cancer screening, hysterectomy, uterus
I'm interested
Share via email
See this study on ClinicalTrials.gov

Sensory, cognitive, motor interactions

This study is about understanding how cognitive, sensory, and motor processes interact. Participants must be a stroke survivor, with a unilateral stroke, leaving arm weakness on one side only, that happened at least 3 months ago.

Principal Investigator: Shanie Jayasinghe
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00025519
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18-80 years old
• had a stroke that happened more than 3 months ago
• have mild-to-moderate weakness on one side only
Exclusion Criteria:

• Non-English speakers
• women who are pregnant
• have a pacemaker
• had a bilateral stroke
Conditions: Brain & Nervous System
Keywords: stroke
I'm interested
Share via email

MT2025-36: Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

This study is about treatment of Melanoma (a kind of skin cancer) that has spread or cannot be surgically removed and has gotten worse after standard treatments. This study includes patients with melanoma from any part of the body except the eye. The main purpose of this study is to learn if the study medicine (tebentafusp), alone or a combination with pembrolizumab, helps patients with advanced melanoma live longer. The combination of pembrolizumab and tebentafusp used in this study is experimental.

Principal Investigator: Benjamin Manning
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00001926
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• unresectable Stage III or Stage IV non-ocular melanoma
• may not be able to do physically strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• women who are pregnant or breastfeeding
• diagnosis of ocular or metastatic uveal melanoma
• history of a another type of cancer
• unable to be retreated with pembrolizumab because of a previous severe side effect
• significant pulmonary or cardiac disease or impaired lung or cardiac function
• known psychiatric or substance abuse disorders
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions: Cancer
Keywords: melanoma, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly.

Principal Investigator: Robert Galvin
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY0016411
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• patients must be >= 12 months and =< 21 years of age at the time of enrollment on Step 0
• patient is suspected of having localized, newly diagnosed HGG, excluding metastatic disease, OR patient has an institutional diagnosis of DIPG
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• female patients who are pregnant are ineligible since there is yet no available information regarding human fetal or teratogenic toxicities
• lactating females are not eligible unless they have agreed not to breastfeed their infants. It is not known whether selinexor is excreted in human milk
Conditions: Cancer
Keywords: Anaplastic Astrocytoma, Diffuse Intrinsic Pontine Glioma, Glioblastoma, Malignant Glioma
I'm interested
Share via email
See this study on ClinicalTrials.gov

CureGN: Cure Glomerulonephropathy Network Version 3.0

The purpose of CureGN3 is to gather a group of people with glomerular disease to create a source of information and blood and urine samples, so that researchers can easily and effectively study glomerular disease.

Principal Investigator: Michelle Rheault
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: SITE00000840
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Diagnosis of Glomerular Disease including MCD (minimal change disease), FSGS (focal segmental glomerulosclerosis), MN (membranous nephropathy), or IgAN (immunoglobulin A nephropathy) on first diagnostic kidney biopsy
• First diagnostic kidney biopsy within 5 years of study enrollment
• Access to first kidney biopsy report and/or slides
• All ages
Exclusion Criteria:

• End Stage Kidney Disease, defined as chronic dialysis or kidney transplant
• Solid organ or bone marrow transplant recipient at time of first kidney biopsy
• Diagnosis of any of the following at the time of first diagnostic kidney biopsy: diabetes mellitus (except gestational or diet controlled), diabetic glomerulosclerosis, systemic lupus erythematosus, HIV infection, active malignancy (except for non-melanoma skin cancer), active Hepatitis B or C infection, defined as positive viral load
Conditions: Kidney, Prostate & Urinary, Rare Diseases
Keywords: Kidney, Glomerular Disease, Clinics and Surgery Center (CSC)
I'm interested
Share via email

COG AALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 147294) in Combination with Nivolumab (NSC # 748726, IND# 147294), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to < 31 Years Old with First Relapse

The overall goal of this study is to determine if treating first relapse B-cell acute lymphoblastic leukemia (B-ALL) with a combination of blinatumomab and nivolumab is more effective than blinatumomab alone.

Principal Investigator: Peter Gordon
Age Group: 1 year to 30 years old
This study is NOT accepting healthy volunteers
IRB Number: SITE00001178
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 1 year to 30 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 1 to 30 years old
• must have first relapse of CD19+ B-ALL (relapse blasts must express CD19)
• must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
• see link to clinicaltrials.gov for completed Inclusion criteria
Exclusion Criteria:

• other types of blood disorders including: B-lymphoblastic lymphoma (B-LLy), Burkitt leukemia/lymphoma or mature B-cell leukemia, Philadelphia chromosome positive (Ph+) B-ALL, mixed phenotype acute leukemia (MPAL), known Charcot-Marie-Tooth disease, MYC translocation associated with mature (Burkitt) B-cell ALL
• active, uncontrolled infection
• significant central nervous system pathology including history of severe neurologic disorder or autoimmune disease with CNS involvement
• women who are pregnant or breastfeeding
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions: Cancer
Keywords: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
I'm interested
Share via email
See this study on ClinicalTrials.gov

Autonomous Digital CBT Intervention for Opioid Use Disorder in Individuals with Co-Occurring Internalizing Disorders

This study is about a new mobile application program called “NEAT-O” which stands for Negative Emotions and Addiction Tools for Opioid Use Disorder. It is designed for people who are struggling with opioid use and also facing issues with anxiety or depression. We are testing the program to see if it's helpful and easy to use. We would also like to learn about your experiences and perspectives on coping strategies for managing symptoms related to opioid use disorder, anxiety, and depression.

Principal Investigator: Justin Anker
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022055
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• adults ages 22 to 65
• diagnosis of Opioid use disorder (OUD)
• diagnosis of panic disorder with or without agoraphobia, generalized anxiety disorder, social anxiety disorder, or major depression
• in treatment for OUD using MOUD (medications for opioid use disorder)
• access to an internet-enabled smartphone for the duration of the study
• living in the United States
Exclusion Criteria:

• diagnosis of psychosis
• current institutionalization (e.g., jail, hospital)
• women who are pregnant
• unable to speak English
Conditions: Mental Health & Addiction
Keywords: mental illness, opioid addiction, Opioid use disorder, OUD, anxiety, depression

ABATE-IP-18: A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are Colonized with Nontuberculous Mycobacteria (The ABATE Study) (ABATE)

The purpose of this research study is to test the safety of giving two separate 5-day infusions (starting on Day 1 and again around Day 15) through a vein with a drug called gallium nitrate. Laboratory tests suggest that this drug may be able to fight Nontuberculous Mycobacteria (NTM) infections

Principal Investigator: Joanne Billings
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020585
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of cystic fibrosis
• persistent Nontuberculous Mycobacterium lung infection (NTM)
• able to expectorate sputum
• enrolled in the CFF Patient Registry
• see link to clinicaltrials.gov for complete inclusion & exclusion criteria
Exclusion Criteria:

• history of solid organ or hematological transplantation
• current diagnosis of osteoporosis
• women who are pregnant or breast feeding
• men and women who are unwilling to practice a medically acceptable form of contraception
Conditions: Rare Diseases, Breathing, Lung & Sleep Health
Keywords: CF, Cystic Fibrosis, Nontuberculous Mycobacterium Infection, NTM, Clinics and Surgery Center (CSC)

Cardiac Sarcoidosis Consortium

This is a registry study. The Cardiac Sarcoidosis Consortium (CSC) is an international, multicenter partnership among physicians and allied professionals at major medical centers with the unifying purpose to learn more about cardiac sarcoidosis through collaborative research.

Principal Investigator: Henri Roukoz
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: 1209M20465
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• People who have been diagnosed with Cardiac sarcoidosis (CS)
• History of ventricular tachycardia or fibrillation
• Ventricular arrhythmias treated medically or with an implanted device
Conditions: Heart & Vascular
Keywords: Ventricular Tachycardia, Cardiac sarcoidosis, ablation, cardiac ablation
I'm interested
Share via email

Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics: R33 Phase

This study will look at the effects of treatment combining Comprehensive Behavioral Intervention for Tics (CBIT) and Transcranial Magnetic Stimulation (TMS) for young people who have tic disorder. Participants must be 12- 21 years old and able to have an MRI. All participants will receive 10 daily sessions of CBIT, a well-established behavioral treatment that is considered to be the first treatment for tics. Participants will also be assigned randomly (by chance) to receive TMS or a sham (treatment not delivered) just before each CBIT session. The device for TMS delivers electromagnetic stimulation to a specific area of the brain with a small coil on the scalp. The effectiveness of the CBIT for the two groups, with and without the TMS, will be compared.

Principal Investigator: Christine Conelea
Age Group: 12 years to 21 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023755
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 12 years to 21 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• between the ages of 12 – 21
• currently experiencing chronic motor and/or vocal tics
• able to undergo MRI
• study staff will review additional exclusion criteria
Exclusion Criteria:

• currently receiving therapy focused on tics
• currently taking neuroleptic/antipsychotic medications
Conditions: Brain & Nervous System, Children's Health, Mental Health & Addiction
Keywords: TMS, Tourette's syndrome, Vocal tics, CBIT, Motor tics, Tic Disorder
I'm interested
Share via email
See this study on ClinicalTrials.gov

Evaluation of Microbiota Transplant Therapy in Patients with Alopecia Areata

The purpose of this study is to determine if microbiota transplant therapy (MTT) is an effective treatment for patients with alopecia areata, alopecia totalis, and alopecia universalis. We will be testing two different ways of doing the Microbiota transplant therapy (MTT): half the people who choose to be part of this study will take antibiotics before the transplant and half will take placebo antibiotics. We will collect 5 types of samples (2 or more times during the study): blood samples, skin samples, skin swabs, hair, and fecal samples.

Principal Investigator: Maria Hordinsky
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023721
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 75 years of age
• moderate to severe alopecia areata with at least 30% scalp hair loss
• hair loss lasting for at least 3 months
• must be willing to stop using other types of medications to treat Alopecia Areata throughout the study
• evidence of active, ongoing regrowth of hair
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• active medical conditions or cancer
• current gastrointestinal infection or use of antibiotics
• current treatment for gastrointestinal diagnosis or previous GI surgery (past 3 months)
• women who are pregnant or breastfeeding
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions: Dermatology (Skin, Hair & Nails)
Keywords: alopecia, Hair loss
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2013-06C : Treatment of graft Failure after HSCT

The primary purpose of this study is to record outcomes and patient characteristics in the Masonic Cancer Center and BMT databases for patients undergoing a second transplant using a haploidentical donor, an unrelated donor or umbilical cord blood. The data will be analyzed for transplant “milestones” such as time to blood count recovery (engraftment) and how patients are doing at 3 months and 6 months after the transplant. Participation in this study will not alter treatment or medical care. All information for this study will be collected from medical records.

Principal Investigator: Troy Lund
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: 1404M49341
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• patients with primary or secondary HSCT graft failure
• see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria
Exclusion Criteria:

• uncontrolled infection at the time of transplant
• patients with Fanconi Anemia or other DNA breakage syndromes
Keywords: Clinics and Surgery Center (CSC), Failure, Hematopoietic Stem Cell Transplantation, HSCT
I'm interested
Share via email
See this study on ClinicalTrials.gov

Effectiveness of Screening and Decolonization of S. aureus to Prevent S. aureus Surgical Site Infections in Surgery Outpatients

The purpose of this study is to determine the most effective ways to get rid of Staph aureus on body surfaces before surgery. We will determine if the participants can effectively get rid of the bacteria with the simple application of various treatment methods assigned to them. We will study if these methods are useful and cost effective in preventing the infections after surgery.

Principal Investigator: Susan Kline, MD
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00019575
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• people who are scheduled for orthopedic, urology, neuro, otolaryngology, plastic and general surgery or OB/GYN surgery
• surgery is scheduled for at least 10 days following entry into the study
• have not taken antibiotics in the week before surgery
• will have a skin incision
Exclusion Criteria:

• surgery scheduled less than 10 days after the baseline cultures
I'm interested
Share via email
See this study on ClinicalTrials.gov

Effects of relighting on smoke toxicant deliveries and subjective smoking measures

The purpose of this study is to understand how relighting cigarettes affects the level of toxicants inhaled during smoking, compared to smoking non-relit cigarettes.

Principal Investigator: Irina Stepanov
Age Group: 21 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00021107
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 21 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• at least 21 years old
• smoking at least 5 cigarettes/day for at least 1 year
• engaging in relighting behavior – extinguishing, saving, and later relighting unfinished cigarette butts
• no attempts to quit smoking in the past month nor intentions to quit in the next month
• systolic blood pressure < 160, diastolic blood pressure < 100 and heart rate < 105 bpm
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• current or recent alcohol or drug abuse problems, use of substances of abuse (other than marijuana due to high prevalence of co-use) within the past month
• women who are planning to become pregnant, pregnant or breastfeeding
Conditions: Cancer, Community Health
Keywords: Cigarette, Nicotine Dependence, Smoking, Tobacco

Investigating EEG as a biomarker for tinnitus improvement after bimodal stimulation

This study is about understanding how TMS affects the balance between inhibitory and facilitatory processes in the motor cortex. The study includes an experimental device, specifically transcranial magnetic stimulation (TMS), electroencephalography (EEG), and electromyography (EMG). TMS is a non-invasive brain stimulation method to probe brain activity. EEG is used to record brain activity through electrodes placed on the head, while EMG measures muscle activity through sensors attached to the skin.

Principal Investigator: Peggy Nelson
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00025649
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• People with Tinnitus: subjective tinnitus, have not started wearing hearing aids in the last 3 months, and don't have implanted electronic devices and willing to commit to 6 weeks of study
• Healthy Volunteers: have not started wearing hearing aids in the last 3 months and willing to commit to 6 weeks of study
Exclusion Criteria:

• People with objective tinnitus
Conditions: Brain & Nervous System
Keywords: Tinnitus
I'm interested
Share via email

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years& Less than 18 Years of Age with Alopecia Areata

We are conducting a research study for children ages 6-17 with patchy Alopecia Areata (AA). The purpose of this research study is to learn more about the safety, tolerability and efficacy of an investigational drug called Baricitinib. This study will compare the investigational drug to a placebo (inactive substance) to see how well the investigational drug works.

Principal Investigator: Maria Hordinsky
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: SITE00001967
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• children 6 to 18 years old
• at or above the 5th percentile of weight for age
• diagnosis of Alopecia Areata (AA) for at least 1 year
• current AA episode of at least 6 months duration with hair loss encompassing 50% or more of the scalp
• history of trial and failure with at least 1 available treatment
• history of psychological counseling related to AA
Exclusion Criteria:

• primarily diffuse type of AA (characterized by diffuse hair shedding)
• currently experiencing other forms of alopecia including, but not limited to: trichotillomania, TE, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis)
Conditions: Dermatology (Skin, Hair & Nails)
Keywords: AA, Alopecia Areata, hair loss
I'm interested
Share via email

An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan (LNP023) in C3 glomerulopathy or idiopathic immune-complex- membranoproliferative glomerulonephritis

This study is about finding out if long-term use of iptacopan (LNP023) is safe and can help others who have C3 Glomerulopathy (C3G) or idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN). This study if for people who have completed either the IC-MPGN Phase 3 CLNP023B12302 “APPARENT” study or the C3G Phase 3 CLNP023B12301 “APPEAR-C3G” study.

Principal Investigator: Nattawat Klomjit
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00025118
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 100 years old
• diagnosis of IC-MPGN (immune-complex membranoproliferative glomerulonephritis) or C3G (C3 glomerulopathy)
• must have completed the treatment period of the CLNP023X2202, CLNP023B12301 or CLNP023B12302 study on study drug
Exclusion Criteria:

• active systemic bacterial, viral or fungal infection
• history or current diagnosis of ECG abnormalities
• history of HIV or any other immunodeficiency disease
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Kidney, Prostate & Urinary
Keywords: C3 Glomerulopathy, Glomerulonephritis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Biorepository to Support ALS Research in Minnesota

The purpose of the study is to establish and maintain a biorepository of tissue and biospecimen samples relevant to Amyotrophic Lateral Sclerosis (ALS) research. We will obtain, store, and catalogue peripheral blood mononuclear cells (PBMCs), blood and blood components, skin punch biopsy samples, and cerebral spinal fluid (CSF) from people living with ALS, linked to clinical datasets, to advance ALS research.

Principal Investigator: David Walk
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022317
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• People living with ALS: people with a confirmed diagnosis of ALS
• Controls: people who have a neurological disorder other than ALS for which a comparison will assist in medical discovery Healthy controls: Individuals without ALS or other neurological disorders.
Exclusion Criteria:

• age less than 18 or greater than 90
Conditions: Brain & Nervous System, Rare Diseases, Rare Diseases
Keywords: ALS, amyotrophic lateral sclerosis, Clinics and Surgery Center (CSC)
I'm interested
Share via email

Altered cortical representation of paretic leg muscles in individuals with stroke: a TMS-based motor mapping study

This research study is aimed at finding the changes in brain activity of people who have experienced a stroke and how it may affect their movement coordination during walking. Participants will be asked to walk on a treadmill at a comfortable speed while their movement pattern will be measured. Participants will also undergo magnetic resonance imaging (MRI) scan and assessment of the brain activity using Transcranial magnetic stimulation (TMS) which is a non-invasive brain stimulation method often used to stimulate nerve cells in the brain and assess connectivity between the brain and individual muscles.

Principal Investigator: Jacqueline Palmer
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00024574
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18-85 years of age
• have either ischemic or hemorrhagic stroke at least six months ago
• had a single stroke or multiple strokes on the same side of the brain
• have residual paresis in the lower extremity
• can walk at least 10 feet with or without assistive device
• fluent in English
Exclusion Criteria:

• history of seizures
• take medications that could lower seizure thresholds
• history of brain injury or other CNS disease (with exception of stroke
• have a pacemaker or metal or electric implant in the head, neck, or chest area
• have non-MR compatible implants
Conditions: Brain & Nervous System
Keywords: Stroke
I'm interested
Share via email

Kinematic signatures of postural instability and gait in healthy adults

The purpose of this research is to better understand balance and walking in a healthy adult population to compare to patients with Parkinson’s Disease. This research study uses small wearable devices that attach to your clothing and can measure your body’s location while performing walking and balance tests. We expect that you will be in this research study at the Minnesota State Fair for approximately 10-15 minutes.

Principal Investigator: Robert McGovern, MD
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00009709
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers

Exclusion Criteria:

• any neurological disease
• history of vertigo
• dementia of sufficient severity to impair the ability to make decisions
Conditions: Brain & Nervous System
Keywords: Balance, Movement, Parkinson's Disease, D2D
I'm interested
Share via email

10,000 Families Study

The purpose of this study is to study the evolution of early life risk factors that may lead to cancer and other conditions. This is a prospective cohort study of families who reside in Minnesota.

Principal Investigator: Jen Poynter
Age Group: Not specified
This study is also accepting healthy volunteers
IRB Number: STUDY00000877
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is also accepting healthy volunteers
Inclusion Criteria:

• 1st Participant: 18+ living in MN
• Other family members: All ages and must live in MN, ND, SD, IA, or WI
• Participants ages 0-17 must have a parent consent to their participation and assist with study activities
Exclusion Criteria:

• Unwilling or unable to provide DNA and blood sample
• Does not have at least 1 living family member in MN IA, ND, SD, or WI
Conditions: Cancer, Microbiota, Prevention & Wellness
Keywords: Minnesota, PFAS, environment, exposures, family, genetics, glyphosate, lifestyle, radon, 10KFS, D2D
Visit study website
I'm interested
Share via email

Balance4Mobility: Effects of Walkasins Use on Clinical Outcomes of Gait and Balance Function in Individuals with Peripheral Neuropathy and Balance Problems &#8211; A Randomized Control Trial

The main purpose of this study is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. Walkasins have been developed to improve balance and walking by enhancing a person’s ability to feel the pressure beneath his/her feet as he/she walks.

Principal Investigator: Islam Zineldin
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00025212
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 55 years old
• able to complete all activities without the use of an assistive device
• diagnosis of peripheral neuropathy (if due to chemotherapy, must be 1 year after completion)
• experiencing problems with gait or balance
Exclusion Criteria:

• able to stand on one leg for at least 30 seconds
• acute thrombophlebitis, including deep vein thrombosis, or severe peripheral vascular disease
• lymphedema
• swelling, infection, inflamed area of skin or eruptions on the lower leg
• weigh more than 300 pounds
Conditions: Bone, Joint & Muscle, Brain & Nervous System
Keywords: Peripheral Neuropathies, Balance, Gait Disorders
I'm interested
Share via email
See this study on ClinicalTrials.gov

Studying the visual attention and memory in relation to the brain dynamics in healthy adults

This is a study that will investigate the relationship between visual attention and memory and brain dynamics in healthy volunteers by manipulating brain oscillations with transcranial alternating current stimulation (tACS).

Principal Investigator: Alexander Opitz
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00020160
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is also accepting healthy volunteers
Inclusion Criteria:

• age 18–40 years
• healthy volunteers with no history of neurological or psychiatric illness
• normal or corrected-to-normal vision
Exclusion Criteria:

• history of neurological or psychiatric disorders
• metal implants or implanted electronic medical devices
• women who are pregnant
Conditions: Mental Health & Addiction
Keywords: cognition, EEG, memory, neuroscience, noninvasive brain stimulation
I'm interested
Share via email

Non-Invasive Sleep and Circadian Rhythm Assessment Pre- and Post-surgery in Cushing Disease

The goal of this study is to see if using in-home sleep activity monitoring may help understand sleep problems that occur before and after surgical treatment for Cushing Disease.

Principal Investigator: Takako Araki
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022764
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• Aged 18 years or older
• Their own legal guardian
• Confirmed Cushing's Disease (CD) by biochemical test and brain MRI imaging
• Scheduled for surgery to treat CD
• Receiving care through an Endocrinology or Neurosurgery clinic
• Able to complete the self-report their health/wellbeing and sleep diary information
Exclusion Criteria:

• Biochemical and/or brain MRI imaging test with inconclusive results
• Patients not electing for surgical intervention for CD
Conditions: Breathing, Lung & Sleep Health, Diabetes & Endocrine, Rare Diseases
Keywords: CD, Cushing Disease
I'm interested
Share via email

A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature (ISS)

This research is being done to learn if a study drug called vosoritide can help children who are shorter than should be for their age to grow.

Principal Investigator: Brad Miller, MD, PhD
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
IRB Number: STUDY00023763
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 3 to 10 years old if a girl
• 3 to 11 years old if a boy
• have short stature compared to others of the same gender and age with no known cause
• able to move and stand without help
Exclusion Criteria:

• known chromosomal imbalance or genetic variant causing short stature syndrome
• previous treatment with a growth promoting agent
Conditions: Diabetes & Endocrine, Rare Diseases
Keywords: idiopathic short stature, ISS, short
I'm interested
Share via email
See this study on ClinicalTrials.gov

EFC17574: A Phase 3, single-arm, multicenter, multinational, open label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged >= 12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX (ATLAS-NEO)

A study to test a medicine (fitusiran) injected under the skin for preventing bleeding episodes in male adolescent or adult participants with severe Hemophilia.

Principal Investigator: Jacob Cogan
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00017896
Show full eligibility criteria
Hide eligibility criteria
Sex: Male
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 12 years or older
• diagnosis of severe congenital hemophilia A or B
• participants currently not on prophylaxis (CFC or BPA on-demand): A minimum of 4 bleeding episodes requiring BPA (inhibitor participants) or CFC (non-inhibitor participants) treatment within the last 6 months
Exclusion Criteria:

• co-existing bleeding disorders other than congenital hemophilia A or B
• current participation in immune tolerance induction therapy (ITI)
• prior treatment with gene therapy
• acute hepatitis, ie, hepatitis A, hepatitis E, acute or chronic hepatitis B infection
• additional exclusion criteria apply (study staff will review)
Conditions: Blood Disorders
Keywords: Hemophilia
I'm interested
Share via email
See this study on ClinicalTrials.gov

ALX-HPP-501: An Observational,Longitudinal Prospective, Long-term Registry of Patients with Hypophosphatasia

This is a long-term registry is designed to collect data on hypophosphatasia (HPP) to better understand the condition and learn more about the disease, how patients feel about living with HPP and effect of HPP on the patients wellbeing and health. The study will look at participant’s medical records and health questionnaires about the health status of patients. This study collects observational data from clinical care and does not involve any treatment for HPP or administration of medication for HPP.

Principal Investigator: Kyriakie Sarafoglou
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00004936
Show full eligibility criteria
Hide eligibility criteria
Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• confirmed diagnosis of HPP.
• documented alkaline phosphatase (ALP) activity below the lower limit of normal for age and sex, or a documented ALPL gene mutation.
• able to read and speak English
Exclusion Criteria:

• currently participating in an Alexion-sponsored clinical trial
Conditions: Rare Diseases
Keywords: HPP, Hypophosphatasia
I'm interested
Share via email
See this study on ClinicalTrials.gov